2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

More documents

Recommendations

Info

This publication is supported by an educational donation provided by: Support for this program is funded through
Page 1 and 2:
AMERICAN SOCIETY OF CLINICAL ONCOLO
Page 3 and 4:
American Society of Clinical Oncolo
Page 5 and 6:
American Society of Clinical Oncolo
Page 7 and 8:
New Looks and Challenges for Cooper
Page 9 and 10:
Genitourinary Cancer Best Use of Im
Page 11 and 12:
Research and Standard of Care: Lung
Page 13 and 14:
Practice Management and Information
Page 15 and 16:
2012 ASCO Annual Meeting Disclosure
Page 17 and 18:
Matti S. Aapro, MD Clinique De Geno
Page 19 and 20:
Hedy Lee Kindler, MD The University
Page 21 and 22:
Douglas E. Wood, MD University of W
Page 23 and 24:
Mary Lou Smith, JD, MBA Research Ad
Page 25 and 26:
ASCO and Conquer Cancer Foundation
Page 27 and 28:
Letter from the Editor The theme of
Page 29 and 30:
Adjuvant Therapy for Older Women wi
Page 31 and 32:
TREATMENT FOR OLDER WOMEN WITH BREA
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
MANAGEMENT OF T1 BREAST CANCERS the
Page 39 and 40:
MANAGEMENT OF T1 BREAST CANCERS Tab
Page 41 and 42:
MANAGEMENT OF T1 BREAST CANCERS Tab
Page 43 and 44:
MANAGEMENT OF T1 BREAST CANCERS 93.
Page 45 and 46:
MANAGEMENT OF T1 BREAST CANCERS 1 c
Page 47 and 48:
ADJUVANT ENDOCRINE THERAPY reductio
Page 49 and 50:
ADJUVANT ENDOCRINE THERAPY which ra
Page 51 and 52:
ADJUVANT ENDOCRINE THERAPY assay is
Page 53 and 54:
A DICKENS TALE OF THE TREATMENT OF
Page 55 and 56:
TREATMENT OF ADVANCED BREAST CANCER
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
A FRESH LOOK AT DUCTAL CARCINOMA IN
Page 67 and 68:
DCIS: OPPORTUNITIES AND UNCHARTED W
Page 69 and 70:
DCIS: OPPORTUNITIES AND UNCHARTED W
Page 71 and 72:
Ductal Carcinoma In Situ, and the I
Page 73 and 74:
DCIS AND INFLUENCE OF RISK FACTORS
Page 75 and 76:
KEY QUESTIONS IN THE LOCO-REGIONAL
Page 77 and 78:
POSTMASTECTOMY RADIATION AND PARTIA
Page 79 and 80:
The Appropriate Extent of Surgery f
Page 81 and 82:
SURGERY FOR EARLY-STAGE BREAST CANC
Page 83 and 84:
BIOLOGY AND LOCAL THERAPY DECISIONS
Page 85 and 86:
Clinical and Imaging Surveillance F
Page 87 and 88:
SURVEILLANCE FOLLOWING BREAST CANCE
Page 89 and 90:
SURVEILLANCE FOLLOWING BREAST CANCE
Page 91 and 92:
Advanced Imaging Techniques for the
Page 93 and 94:
IMAGING TECHNIQUES FOR BREAST CANCE
Page 95 and 96:
IMAGING TECHNIQUES FOR BREAST CANCE
Page 97 and 98:
Update of the Oxford Overview: New
Page 99 and 100:
UPDATE OF THE OXFORD OVERVIEW Fig.
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
UPDATE OF THE OXFORD OVERVIEW Overv
Page 107 and 108:
Gene Patents and Personalized Medic
Page 109 and 110:
GENE PATENTS AND EFFECTS ON PERSONA
Page 111 and 112:
Chemoprevention for Breast Cancer:
Page 113 and 114:
CHEMOPREVENTION FOR BREAST CANCER T
Page 115 and 116:
CHEMOPREVENTION FOR BREAST CANCER C
Page 117 and 118:
CONTROVERSIES IN PROSTATE CANCER: P
Page 119 and 120:
PROSTATE CANCER RISK REDUCTION men
Page 121 and 122:
PROSTATE CANCER RISK REDUCTION Auth
Page 123 and 124:
PSA SCREENING: HARMS WITHOUT CLEAR
Page 125 and 126:
PSA SCREENING: HARMS WITHOUT CLEAR
Page 127 and 128:
GLIOBLASTOMA: TAKING THE STANDARD O
Page 129 and 130:
GLIOBLASTOMA: BIOLOGY, GENETICS AND
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
FUTURE DIRECTIONS IN GBM THERAPY pr
Page 137 and 138:
FUTURE DIRECTIONS IN GBM THERAPY Ch
Page 139 and 140:
ESTABLISHING TREATMENTS FOR GLIOBLA
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Current Concepts in Brain Tumor Ima
Page 147 and 148:
CONCEPTS IN BRAIN TUMOR IMAGING tum
Page 149 and 150:
CONCEPTS IN BRAIN TUMOR IMAGING Aut
Page 151 and 152:
PERSPECTIVES ON HEADLINE-MAKING NEW
Page 153 and 154:
TTF THERAPY IN GLIOBLASTOMA Fig. 1.
Page 155 and 156:
TTF THERAPY IN GLIOBLASTOMA istics.
Page 157 and 158:
TTF THERAPY IN GLIOBLASTOMA because
Page 159 and 160:
Limitations of Adaptive Clinical Tr
Page 161 and 162:
LIMITATIONS OF ADAPTIVE CLINICAL TR
Page 163 and 164:
LIMITATIONS OF ADAPTIVE CLINICAL TR
Page 165 and 166:
Capturing the Patient Perspective:
Page 167 and 168:
PATIENT-REPORTED OUTCOMES AS TRIAL
Page 169 and 170:
PATIENT-REPORTED OUTCOMES AS TRIAL
Page 171 and 172:
NEW LOOKS AND CHALLENGES FOR COOPER
Page 173 and 174:
NCI NATIONAL CLINICAL TRIALS NETWOR
Page 175 and 176:
Successful Integration of Cooperati
Page 177 and 178:
COG: GIVING NEW MEANING TO COOPERAT
Page 179 and 180:
A Critical Review of the Enrollment
Page 181 and 182:
BLACK PATIENTS AND CANCER CLINICAL
Page 183 and 184:
BLACK PATIENTS AND CANCER CLINICAL
Page 185 and 186:
Trastuzumab Emtansine (T-DM1): Hitc
Page 187 and 188:
T-DM1 AND THERAPEUTIC ANTIBODIES ag
Page 189 and 190:
TARGETING CD30 IN HODGKIN LYMPHOMA
Page 191 and 192:
TARGETING CD30 IN HODGKIN LYMPHOMA
Page 193 and 194:
EARLY DRUG DEVELOPMENT: CASTING A W
Page 195 and 196:
Table 1. Response Rates in Expanded
Page 197 and 198:
Drug Development in the Era of Pers
Page 199 and 200:
that the core pathway is not comple
Page 201 and 202:
This situation is not surprising, g
Page 203 and 204:
Practical Management of Immune-Rela
Page 205 and 206:
the anterior pituitary axis is invo
Page 207 and 208:
TARGETING CRITICAL MOLECULAR ABERRA
Page 209 and 210:
Abl suppression; and 3) the early e
Page 211 and 212:
50% 50% 100% Change in Tumor Size m
Page 213 and 214:
vanced solid tumors, even if they a
Page 215 and 216:
Targeting Molecular Aberrations in
Page 217 and 218:
date. With the advent of gene expre
Page 219 and 220:
consortium to facilitate the testin
Page 221 and 222:
ETHICAL CHALLENGES OF HEALTH CARE R
Page 223 and 224:
HEALTH CARE REFORM AND ONCOLOGY dev
Page 225 and 226:
HEALTH CARE REFORM AND ONCOLOGY aut
Page 227 and 228:
INTERNATIONAL VARIATION IN UNDERSTA
Page 229 and 230:
midcareer physician; in one cross-s
Page 231 and 232:
Table 1. Recommendations for Person
Page 233 and 234:
stances (e.g., stage of career, fam
Page 235 and 236:
elationship” is also acknowledged
Page 237 and 238:
Conclusion In more individualistic
Page 239 and 240:
The Oncologist’s Duty to Provide
Page 241 and 242:
an external observer, but to the pe
Page 243 and 244:
MEDICAL ERRORS IN CANCER CARE: PREV
Page 245 and 246:
DISCLOSING MEDICAL ERRORS Disclosur
Page 247 and 248:
DISCLOSING MEDICAL ERRORS Author’
Page 249 and 250:
PREVENTING MEDICAL ERRORS more diff
Page 251 and 252:
“PERSONALIZED” ONCOLOGY FOR COL
Page 253 and 254:
0.001), progression-free survival (
Page 255 and 256:
mately 40% of patients with colorec
Page 257 and 258:
Table 1. Tumor Marker Utility Gradi
Page 259 and 260:
treatment (tx) for metastatic color
Page 261 and 262:
The Interventional Radiologist Role
Page 263 and 264:
effect. The most common drug that h
Page 265 and 266:
gone forever, no further therapy is
Page 267 and 268:
is irrelevant if it is already rese
Page 269 and 270:
Resection and Thermal Ablation of L
Page 271 and 272:
Author’s Disclosures of Potential
Page 273 and 274:
Minimally Invasive Surgery of Recta
Page 275 and 276:
outcomes; local, wound-site, and di
Page 277 and 278:
Authors’ Disclosures of Potential
Page 279 and 280:
CAO/ARO 04 study—which added oxal
Page 281 and 282:
STAGE III COLON CANCER: WHAT WORKS,
Page 283 and 284:
Table 1. Comparison of Fluoropyrimi
Page 285 and 286:
tients with stages II and III color
Page 287 and 288:
ized by high fruit, vegetable, poul
Page 289 and 290:
Exercise Change trial: a randomized
Page 291 and 292:
A New Direction for Pancreatic Canc
Page 293 and 294:
Table 1. FOLFIRINOX versus Gemcitab
Page 295 and 296:
The Southwest Oncology Group (SWOG)
Page 297 and 298:
A Matter of Timing: Is There a Role
Page 299 and 300:
an OS benefit with radiation therap
Page 301 and 302:
a dose of 50.4 Gy to 59.4 Gy of rad
Page 303 and 304:
more commonly given for APC, specia
Page 305 and 306:
subcutaneous bolus or infusion. Hal
Page 307 and 308:
patients are cared for completely w
Page 309 and 310:
Varying Lymphadenectomies for Gastr
Page 311 and 312:
Table 1. Regional Lymph Nodes of th
Page 313 and 314:
Conclusion There are clear differen
Page 315 and 316:
Will Disease Heterogeneity Help Def
Page 317 and 318:
prematurely due to poor accrual. 18
Page 319 and 320:
Adjuvant Treatments for Localized A
Page 321 and 322:
ADJUVANT TREATMENT FOR GASTRIC CANC
Page 323 and 324:
LIVER-DIRECTED THERAPEUTIC OPTIONS
Page 325 and 326:
ated with unique dose distributions
Page 327 and 328:
HCC, with encouraging outcomes in e
Page 329 and 330:
tion. Advanced computer-based image
Page 331 and 332:
a 5-year survival rate of 70% follo
Page 333 and 334:
THE MANAGEMENT OF LESS COMMON BUT C
Page 335 and 336:
Fig 1. PubMed publications and clin
Page 337 and 338:
of therapeutic options, patient sel
Page 339 and 340:
less informative than the GRETCH an
Page 341 and 342:
Table 3. New Agents/Regimens under
Page 343 and 344:
combined with concurrent transarter
Page 345 and 346:
to optimize the use of erlotinib by
Page 347 and 348:
Optimal Use of Imaging to Guide Tre
Page 349 and 350:
enhancement seen. Furthermore, the
Page 351 and 352:
CASTRATION-RESISTANT PROSTATE CANCE
Page 353 and 354:
Fig. 1. FDA regulatory approvals in
Page 355 and 356:
Prognostic, Predictive, and Surroga
Page 357 and 358:
adhesion molecule and further chara
Page 359 and 360:
and treatment options are expanding
Page 361 and 362:
KIDNEY CANCER BIOLOGY AND THERAPEUT
Page 363 and 364:
Prognostic Factors in Advanced RCC
Page 365 and 366:
cell immunotherapy in which a small
Page 367 and 368:
New Developments in Urothelial Canc
Page 369 and 370:
Novel Approaches in Advanced Urothe
Page 371 and 372:
10. Albers P, Park SI, Niegisch G,
Page 373 and 374:
700 at a dose of 400 mg twice daily
Page 375 and 376:
therapy for nonmetastatic prostate
Page 377 and 378:
ADJUVANT THERAPY FOR OLDER PATIENTS
Page 379 and 380:
Adjuvant Systemic Therapy Adjuvant
Page 381 and 382:
with early-stage breast cancer were
Page 383 and 384:
clinical trials to generate additio
Page 385 and 386:
Adjuvant Treatment of Older Patient
Page 387 and 388:
OLDER PATIENTS WITH LUNG CANCER Fig
Page 389 and 390:
OLDER PATIENTS WITH LUNG CANCER adj
Page 391 and 392:
Considerations and Controversies in
Page 393 and 394:
OLDER PATIENTS WITH ADVANCED CANCER
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
RECENT CLINICAL HIGHLIGHTS IN GYNEC
Page 401 and 402:
GLOBAL ADVANCES IN GYNECOLOGIC ONCO
Page 403 and 404:
GLOBAL ADVANCES IN GYNECOLOGIC ONCO
Page 405 and 406:
The European Society of Gynaecologi
Page 407 and 408:
ESGO EDUCATIONAL AND RESEARCH ACTIV
Page 409 and 410:
UPFRONT TREATMENT OF OVARIAN CANCER
Page 411 and 412:
ANTIANGIOGENICS AND PARP INHIBITORS
Page 413 and 414:
ANTIANGIOGENICS AND PARP INHIBITORS
Page 415 and 416:
Intraperitoneal Treatment in Ovaria
Page 417 and 418:
INTRAPERITONEAL TREATMENT IN OVARIA
Page 419 and 420:
Dose-Dense Chemotherapy and Neoadju
Page 421 and 422:
CHEMOTHERAPY FOR OVARIAN CANCER Fig
Page 423 and 424:
CHEMOTHERAPY FOR OVARIAN CANCER whi
Page 425 and 426:
UTERINE SARCOMA: CHALLENGING CASES
Page 427 and 428:
HISTOLOGIC FEATURES AND MANAGEMENT
Page 429 and 430:
Page 431 and 432:
Page 433 and 434:
SURGICAL OPTIONS FOR UTERINE SARCOM
Page 435 and 436:
SURGICAL OPTIONS FOR UTERINE SARCOM
Page 437 and 438:
PATIENTS WITH HPV-POSITIVE OROPHARY
Page 439 and 440:
HPV-INDUCED OROPHARYNX CANCER analy
Page 441 and 442:
HPV-INDUCED OROPHARYNX CANCER fract
Page 443 and 444:
Important Early Advances in Squamou
Page 445 and 446:
EARLY ADVANCES IN SCCHN Fig 1. Targ
Page 447 and 448:
Application of Genomic and Proteomi
Page 449 and 450:
GENOMIC AND PROTEOMIC TECHNOLOGIES
Page 451 and 452:
GENOMIC AND PROTEOMIC TECHNOLOGIES
Page 453 and 454:
TREATMENT OF THYROID CANCERS: NEW I
Page 455 and 456:
EVALUATION OF ADVANCED THYROID CANC
Page 457 and 458:
EVALUATION OF ADVANCED THYROID CANC
Page 459 and 460:
Systemic Therapeutic Approaches to
Page 461 and 462:
APPROACHES TO ADVANCED THYROID CANC
Page 463 and 464:
AVOIDING OVERDIAGNOSIS AND OVERTREA
Page 465 and 466:
Table 1. Prevalence of Prostate Can
Page 467 and 468:
Table 3. Potential Risks and Benefi
Page 469 and 470:
Overdiagnosis and Overtreatment of
Page 471 and 472:
een reached by other modeling effor
Page 473 and 474:
east cancer community have FDA-appr
Page 475 and 476:
COSTS OF CANCER CARE: AFFORDABILITY
Page 477 and 478:
REDUCING THE COST OF CANCER CARE Fi
Page 479 and 480:
REDUCING THE COST OF CANCER CARE Th
Page 481 and 482:
REDUCING THE COST OF CANCER CARE de
Page 483 and 484:
Why Hasn’t Genomic Testing Change
Page 485 and 486:
tigators should develop prospective
Page 487 and 488:
MANAGEMENT OF CHRONIC LYMPHOCYTIC L
Page 489 and 490:
PREDICTIVE PARAMETERS IN CLL Table
Page 491 and 492:
PREDICTIVE PARAMETERS IN CLL patien
Page 493 and 494:
Transplant in Chronic Lymphocytic L
Page 495 and 496:
WHEN TO OFFER TRANSPLANTATION IN CL
Page 497 and 498:
WHEN TO OFFER TRANSPLANTATION IN CL
Page 499 and 500:
NEW DEVELOPMENTS IN MYELOPROLIFERAT
Page 501 and 502:
SMALL-MOLECULE INHIBITORS FOR MPN S
Page 503 and 504:
SMALL-MOLECULE INHIBITORS FOR MPN L
Page 505 and 506:
Insights into the Molecular Genetic
Page 507 and 508:
GENETICS OF MYELOPROLIFERATIVE NEOP
Page 509 and 510:
Page 511 and 512:
Page 513 and 514:
Classification of Myeloproliferativ
Page 515 and 516:
CLASSIFICATION AND PROGNOSIS OF MPN
Page 517 and 518:
CLASSIFICATION AND PROGNOSIS OF MPN
Page 519 and 520:
AROUND THE WORLD IN ALMOST 80 MINUT
Page 521 and 522:
LUNG CANCER IN BRAZIL Fig. 1. Relat
Page 523 and 524:
LUNG CANCER IN BRAZIL Fig. 3. Chara
Page 525 and 526:
LUNG CANCER IN BRAZIL Author’s Di
Page 527 and 528:
LUNG CANCER IN CHINA Fig 1. Chinese
Page 529 and 530:
LUNG CANCER IN CHINA well equipped
Page 531 and 532:
Research and Standard of Care: Lung
Page 533 and 534:
LUNG CANCER IN ROMANIA ● Protecti
Page 535 and 536:
LUNG CANCER IN ROMANIA reimbursemen
Page 537 and 538:
A New Model: Physician-Patient Coll
Page 539 and 540:
PHYSICIAN ENGAGEMENT IN ONLINE PATI
Page 541 and 542:
PHYSICIAN ENGAGEMENT IN ONLINE PATI
Page 543 and 544:
LUNG CANCER SCREENING 101 CHAIR Chr
Page 545 and 546:
LUNG CANCER SCREENING The concern i
Page 547 and 548:
LUNG CANCER SCREENING Fig. 1. Guide
Page 549 and 550:
LUNG CANCER SCREENING Fig. 2. Guide
Page 551 and 552:
LUNG CANCER SCREENING 19. Montes RP
Page 553 and 554:
Molecular Testing of Non-Small Cell
Page 555 and 556:
MOLECULAR TESTING AND NSCLC Fig 1.
Page 557 and 558:
MOLECULAR TESTING AND NSCLC logic d
Page 559 and 560:
THYMOMA AND THYMIC CARCINOMA: UPDAT
Page 561 and 562:
MANAGEMENT OF THYMIC CARCINOMA recu
Page 563 and 564:
MANAGEMENT OF THYMIC CARCINOMA Refe
Page 565 and 566:
The Creation of the International T
Page 567 and 568:
ITMIG AS A MODEL FOR RARE DISEASES
Page 569 and 570:
Thymoma: From Chemotherapy to Targe
Page 571 and 572:
SYSTEMIC TREATMENT OF THYMOMA Study
Page 573 and 574:
SYSTEMIC TREATMENT OF THYMOMA cance
Page 575 and 576:
What Is the Best Strategy for Incor
Page 577 and 578:
TREATMENT OF FOLLICULAR LYMPHOMA Fi
Page 579 and 580:
TREATMENT OF FOLLICULAR LYMPHOMA me
Page 581 and 582:
TREATMENT OF FOLLICULAR LYMPHOMA ou
Page 583 and 584:
TREATMENT OPTIONS IN INDOLENT LYMPH
Page 585 and 586:
Page 587 and 588:
Page 589 and 590:
ROLE OF HCT FOR INDOLENT LYMPHOMA T
Page 591 and 592:
ROLE OF HCT FOR INDOLENT LYMPHOMA T
Page 593 and 594:
ROLE OF HCT FOR INDOLENT LYMPHOMA e
Page 595 and 596:
CONTROVERSIES IN MYELOMA: INDUCTION
Page 597 and 598:
TRANSPLANTATION FOR MYELOMA Alterna
Page 599 and 600:
TRANSPLANTATION FOR MYELOMA compare
Page 601 and 602:
TRANSPLANTATION FOR MYELOMA autolog
Page 603 and 604:
CURRENT STATUS OF MYELOMA THERAPY K
Page 605 and 606:
CURRENT STATUS OF MYELOMA THERAPY F
Page 607 and 608:
CURRENT STATUS OF MYELOMA THERAPY T
Page 609 and 610:
Maintenance Therapy for Myeloma: Ho
Page 611 and 612:
MAINTENANCE THERAPY FOR MULTIPLE MY
Page 613 and 614:
Page 615 and 616:
Page 617 and 618:
NEW OPTIONS, NEW QUESTIONS: HOW TO
Page 619 and 620:
THERAPIES FOR PATIENTS WITH METASTA
Page 621 and 622:
Page 623 and 624:
Page 625 and 626:
ANTIEMETICS: CURRENT STANDARDS, EME
Page 627 and 628:
ANTIEMETICS: ASCO GUIDELINE UPDATE
Page 629 and 630:
Page 631 and 632:
Page 633 and 634:
Page 635 and 636:
Chemotherapy-Induced Nausea and Vom
Page 637 and 638:
INCIDENCE AND PREVALENCE OF CHEMOTH
Page 639 and 640:
New Frontiers in Mucositis By Dougl
Page 641 and 642:
MUCOSAL INJURY CAUSED BY CANCER THE
Page 643 and 644:
Page 645 and 646:
Page 647 and 648:
Short- and Long-term Cardiovascular
Page 649 and 650:
Recent Advances in Cardiotoxicity o
Page 651 and 652:
CARDIOTOXICITY OF ANTICANCER THERAP
Page 653 and 654:
CARDIOTOXICITY OF ANTICANCER THERAP
Page 655 and 656:
The Oncologist as the Patient with
Page 657 and 658:
THE ONCOLOGIST AS THE PATIENT OR RE
Page 659 and 660:
Prolonged Febrile Neutropenia in th
Page 661 and 662:
FEBRILE NEUTROPENIA IN PEDIATRIC CA
Page 663 and 664:
FEBRILE NEUTROPENIA IN PEDIATRIC CA
Page 665 and 666:
TREATMENT APPROACHES IN CHILDREN wh
Page 667 and 668:
TREATMENT APPROACHES IN CHILDREN th
Page 669 and 670:
GENETIC COUNSELING OF THE PATIENT W
Page 671 and 672:
CANCER PREDISPOSITION IN CHILDHOOD
Page 673 and 674:
Page 675 and 676:
Page 677 and 678:
Page 679 and 680:
HOW TO MANAGE VERY RARE PEDIATRIC C
Page 681 and 682:
RARE CANCER IN CHILDREN Registries
Page 683 and 684:
Genetic Alterations in Childhood Me
Page 685 and 686:
GENETIC ALTERATIONS IN CHILDHOOD ME
Page 687 and 688:
Desmoid-Type Fibromatosis in Childr
Page 689 and 690:
CHEMOTHERAPY FOR DESMOID TUMOR Tabl
Page 691 and 692:
CHEMOTHERAPY FOR DESMOID TUMOR 14.
Page 693 and 694:
Targeting the Insulin-Like Growth F
Page 695 and 696:
TARGETING THE IGF SYSTEM Fig. 1. Th
Page 697 and 698:
TARGETING THE IGF SYSTEM malignanci
Page 699 and 700:
Hedgehog Pathway in Pediatric Cance
Page 701 and 702:
HEDGEHOG PATHWAY IN PEDIATRIC CANCE
Page 703 and 704:
HEDGEHOG PATHWAY IN PEDIATRIC CANCE
Page 705 and 706:
Development and Refinement of Augme
Page 707 and 708:
ABFM THERAPY FOR PEDIATRIC ALL than
Page 709 and 710:
ABFM THERAPY FOR PEDIATRIC ALL Auth
Page 711 and 712:
RADIOTHERAPY FOR PEDIATRIC HODGKIN
Page 713 and 714:
RADIOTHERAPY FOR PEDIATRIC HODGKIN
Page 715 and 716:
Role of Doxorubicin in Rhabdomyosar
Page 717 and 718:
DOXORUBICIN IN RHABDOMYOSARCOMA 8.
Page 719 and 720:
Identification of Novel Biologic Ta
Page 721 and 722:
NOVEL TARGETS IN THE TREATMENT OF D
Page 723 and 724:
Is Biopsy Safe in Children with New
Page 725 and 726:
SAFETY OF DIPG BIOPSY IN CHILDREN F
Page 727 and 728:
SAFETY OF DIPG BIOPSY IN CHILDREN 1
Page 729 and 730:
CHILDREN WITH DIFFUSE INTRINSIC PON
Page 731 and 732:
Communication and Decision Support
Page 733 and 734:
COMMUNICATION AND DECISION SUPPORT
Page 735 and 736:
Page 737 and 738:
Page 739 and 740:
Planning for the Future: The Role o
Page 741 and 742:
present in the office suite but doe
Page 743 and 744:
Summary and Care Plan are provided.
Page 745 and 746:
DOING IT RIGHT, AND FOR LESS: IMPLE
Page 747 and 748:
CLINICAL PATHWAYS STANDARDIZING PER
Page 749 and 750:
CLINICAL PATHWAYS STANDARDIZING PER
Page 751 and 752:
The Future of Oncology Care with Pe
Page 753 and 754:
quantity. Determining the appropria
Page 755 and 756:
THE ASCO QUALITY ONCOLOGY PRACTICE
Page 757 and 758:
IMPROVING VALUE OF CARE IN ONCOLOGY
Page 759 and 760:
Page 761 and 762:
Page 763 and 764:
PHYSICIAN WELLNESS: COPING WITH REP
Page 765 and 766:
also provides insight on how clinic
Page 767 and 768:
good resource for exploring the pri
Page 769 and 770:
of death or following death and inc
Page 771 and 772:
telephone call to the family, sendi
Page 773 and 774:
New Insights in Cross-Cultural Comm
Page 775 and 776:
CROSS-CULTURAL COMMUNICATION Sideba
Page 777 and 778:
THE ONCOLOGIST, THE PATIENT, AND TH
Page 779 and 780:
estimate of the proportion of their
Page 781 and 782:
exactly the same treatment, even th
Page 783 and 784:
How to Decide Whether to Offer and
Page 785 and 786:
NONSTANDARD THERAPIES FOR ADVANCED
Page 787 and 788:
NONSTANDARD THERAPIES FOR ADVANCED
Page 789 and 790: TARGETED THERAPIES IN TARGETED OR U
Page 791 and 792: TARGETED THERAPY IN SARCOMA rates a
Page 793 and 794: TARGETED THERAPY IN SARCOMA seen in
Page 795 and 796: TARGETED THERAPY IN SARCOMA recepto
Page 797 and 798: Adjuvant Treatment of Gastrointesti
Page 799 and 800: ADJUVANT THERAPY IN HIGH-RISK GASTR
Page 801 and 802: Management of Tyrosine Kinase Inhib
Page 803 and 804: TKI-RESISTANT GIST Primary Imatinib
Page 805 and 806: TKI-RESISTANT GIST Table 2. Clinica
Page 807 and 808: BIOLOGIC PRINCIPLES OF TARGETED COM
Page 809 and 810: COMBINING TARGETED AGENTS IN CLINIC
Page 811 and 812: COMBINING TARGETED AGENTS IN CLINIC
Page 813 and 814: Combination Therapies Building on t
Page 815 and 816: COMBINATIONS FOR MELANOMA agents th
Page 817 and 818: MECHANISMS OF RESISTANCE TO TARGETE
Page 819 and 820: RESISTANCE MECHANISMS TO MAPK INHIB
Page 821 and 822: RESISTANCE MECHANISMS TO MAPK INHIB
Page 823 and 824: Mechanisms of Resistance to Targete
Page 825 and 826: RESISTANCE TO TARGETED THERAPIES IN
Page 827 and 828: RESISTANCE TO TARGETED THERAPIES IN
Page 829 and 830: Translating PI3K-Delta Inhibitors t
Page 831 and 832: THE STORY OF CAL-101 6% of patients
Page 833 and 834: PI3 Kinase in Cancer: From Biology
Page 835 and 836: PI3 KINASE IN CANCER Fig. 1. The PI
Page 837 and 838: PI3 KINASE IN CANCER Fig. 3. In viv
show all

2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?